MargaridaMagalhaes(De Magalhaes)SilvermanMD

Internal Medicine • Iowa City, IA

Hematology/Oncology

Director Stem Cell Transplant

Join to view full profile

Dr. Silverman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Silverman's full profile

Already have an account?

Office
200 Hawkins Dr
University Of Iowa Hospitals & Clinics
Iowa City, IA 52242
Phone+1 319-384-9156

Fax+1 319-353-8383

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1989
University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 1986 - 1988
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1984 - 1986
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1981 - 1984
Univ Porto- Fac MedClass of 1978

Certifications & Licensure

IA State Medical License 1997 - 2027
OH State Medical License 1988 - 2006
PA State Medical License 1991 - 2004
IL State Medical License 1982 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Start of enrollment: 2006 Jan 01
Completed
Phase 4
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Contact, Principal Investigator
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Start of enrollment: 2020 Oct 14
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Randomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2024-09-19
1 citations
A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction.
Kalyan Nadiminti, Kimberly J. Langer, Ehsan Shabbir, Mehrdad Hefazi, Lindsay Dozeman
Blood Cancer Journal. 2021-11-20
3 citations
Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study
Matthew D. Seftel, Pintip Chitphakdithai, John P. Miller, Hati Kobusingye, Brent R. Logan
Transplantation and Cellular Therapy. 2021-04-01

Abstracts/Posters

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma
Margarida Magalhaes Silverman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety a...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other Languages

Portuguese, Spanish